Compare DexCom, Inc. (DXCM) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Synopsys, Inc. — how do they compare? DexCom, Inc. trades at $89.2 (market cap $33.79B), while Synopsys, Inc. trades at $411.99 (market cap $78.68B). The key difference: Synopsys, Inc. is far larger — about 2.3× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | SNPS | |
|---|---|---|
Market Cap | $33.79B | $78.68B |
Sector | Health | Technology |
52-Week High | $89.53 | $625.80 |
52-Week Low | $54.84 | $372.33 |
Enterprise Value | $33.24B | $87.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
